Your browser doesn't support javascript.
loading
Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy.
Sun, Roger; Lerousseau, Marvin; Briend-Diop, Jade; Routier, Emilie; Roy, Severine; Henry, Théophraste; Ka, Kanta; Jiang, Rui; Temar, Nawal; Carré, Alexandre; Laville, Adrien; Hamaoui, Anthony; Laurent, Pierre-Antoine; Rouyar, Angela; Robert, Charlotte; Robert, Caroline; Deutsch, Eric.
Afiliação
  • Sun R; Department of Radiation Oncology, Gustave Roussy, Villejuif, France.
  • Lerousseau M; Université Paris Saclay, Inserm U1030, Radiothérapie Moléculaire et Innovation Thérapeutique, Gustave Roussy, Villejuif, France.
  • Briend-Diop J; Université Paris Saclay, Inserm U1030, Radiothérapie Moléculaire et Innovation Thérapeutique, Gustave Roussy, Villejuif, France.
  • Routier E; Université Paris Saclay, Inserm U1030, Radiothérapie Moléculaire et Innovation Thérapeutique, Gustave Roussy, Villejuif, France.
  • Roy S; Dermatology Unit, Department of Medicine, Gustave Roussy, Villejuif, France.
  • Henry T; Université Paris Saclay, Inserm U981, Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France.
  • Ka K; Dermatology Unit, Department of Medicine, Gustave Roussy, Villejuif, France.
  • Jiang R; Université Paris Saclay, Inserm U981, Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France.
  • Temar N; Université Paris Saclay, Inserm U1030, Radiothérapie Moléculaire et Innovation Thérapeutique, Gustave Roussy, Villejuif, France.
  • Carré A; Imaging Department, Gustave Roussy, Villejuif, France.
  • Laville A; Department of Radiation Oncology, Gustave Roussy, Villejuif, France.
  • Hamaoui A; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Laurent PA; Department of Radiation Oncology, Gustave Roussy, Villejuif, France.
  • Rouyar A; Université Paris Saclay, Inserm U1030, Radiothérapie Moléculaire et Innovation Thérapeutique, Gustave Roussy, Villejuif, France.
  • Robert C; Université Paris Saclay, Inserm U1030, Radiothérapie Moléculaire et Innovation Thérapeutique, Gustave Roussy, Villejuif, France.
  • Robert C; Université Paris Saclay, Inserm U1030, Radiothérapie Moléculaire et Innovation Thérapeutique, Gustave Roussy, Villejuif, France.
  • Deutsch E; Université Paris Saclay, Inserm U1030, Radiothérapie Moléculaire et Innovation Thérapeutique, Gustave Roussy, Villejuif, France.
J Immunother Cancer ; 10(10)2022 10.
Article em En | MEDLINE | ID: mdl-36307149
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia / Melanoma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia / Melanoma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França